Azura Ophthalmics Limited is a groundbreaking brand in the field of ophthalmology, with a focus on harnessing the unique properties of keratolytics to revolutionize the treatment of ocular surface conditions. Through their deep understanding of ocular surface diseases and drug development, Azura Ophthalmics is delivering a new therapeutic class of Ophthalmic Keratolytics to address the needs of underserved ophthalmic conditions. They aim to change the treatment paradigm by offering First-in-Class Ophthalmic Keratolytics that target the core pathophysiology to improve signs, symptoms, and the burden of ophthalmic conditions.

Under the leadership of Marc Gleeson as the Chief Executive Officer, Azura Ophthalmics has assembled a team of experts in the field, including physicians, scientists, and industry professionals. Together, they are dedicated to advancing the science and development of keratolytics for the benefit of patients. Located in Tel Aviv, Israel, Azura Ophthalmics is committed to making a difference in the lives of those suffering from ophthalmic conditions by delivering innovative and effective treatments